Wuchereria bancrofti is a parasitic worm that causes lymphatic filariasis, a neglected tropical disease that affects over 120 million people worldwide. The disease is transmitted to humans through the bites of infected mosquitoes and can lead to debilitating and disfiguring symptoms such as swelling of the limbs, genitals, and breasts. In this article, we will discuss two key antigens of Wuchereria bancrofti: WbL2 and SXP antigen, and their role in the pathogenesis of lymphatic filariasis.

WbL2 Antigen: WbL2 antigen is a protein produced by Wuchereria bancrofti that is recognized by the immune system of infected individuals. It is a promising candidate for use in diagnostic tests for lymphatic filariasis as well as in vaccine development. Studies have shown that the presence of WbL2 antibodies in the blood of infected individuals can be used to accurately diagnose the disease.

SXP Antigen: SXP antigen is another protein produced by Wuchereria bancrofti that has been found to play a role in the pathogenesis of lymphatic filariasis. It is a surface protein that is involved in the attachment of the parasite to the host’s lymphatic system. Research has shown that SXP antigen can induce an immune response in infected individuals, making it a potential target for vaccine development.

The cDNA and recombinant antigens of Wuchereria bancrofti have been used in the study and development of diagnostics, vaccines and therapies for LF. cDNA has been used to identify and characterize specific genes, while the recombinant antigens have been used to develop sensitive and specific diagnostic tests. The antigens have also been used to develop vaccines and therapies for LF, as well as to study the role of different antigens in the pathology of the disease. Furthermore, the antigens have been used to study the transmission dynamics of LF, and to monitor the effects of preventive chemotherapy. In conclusion, the cDNA and recombinant antigens of Wuchereria bancrofti have been applied in a wide range of applications in the field of LF research and control.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.